Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

Extract

Departments of Neurological Surgery (M.D.P., S.M.C.) andNeuro-Oncology (M.K.N.), University of California at San Francisco, San Francisco, CA 94143;Departments of Neuro-Oncology (W.K.A.Y.) andBiostatistics (K.R.H.), The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030;Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD 20892 (H.A.F.);Department of Neurology, University of Michigan, Ann Arbor, MI 48109 (H.S.G., L.J.);Departments of Medicine (H.I.R.) andRadiotherapy (M.P.M.), University of Wisconsin, Madison, WI 53792;Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 (K.L.F.);Departments of Neurology and Hematology/Oncology, Mayo Clinic Jacksonville, Jacksonville, FL 32224 (K.A.J.);College of Pharmacy, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 (J.K.);Office of Clinical Research, University of Pittsburgh, Pittsburgh, PA 15261 (S.C.S.); USA